Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia
Authors:
- Lee-May ChenLCLee-May Chen
- Ernst R LengyelELErnst R Lengyel
- C Bethan PowellCPC Bethan Powell
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (1) , 204-207
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Low-Risk Persistent Gestational Trophoblastic Disease: Outcome After Initial Treatment With Low-Dose Methotrexate and Folinic Acid From 1992 to 2000Journal of Clinical Oncology, 2002
- Is Lack of Response to Single-Agent Chemotherapy in Gestational Trophoblastic Disease Associated with Dose Scheduling or Chemotherapy Resistance?Gynecologic Oncology, 2002
- The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessmentInternational Journal of Gynecological Cancer, 2001
- Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease: A prospective phase II trial of the gynecologic oncology groupCancer, 1987
- Single-dose actinomycin D in the treatment of postmolar trophoblastic diseaseGynecologic Oncology, 1984
- Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: Cost-effective chemotherapyGynecologic Oncology, 1983
- Actinomycin D toxicity in the treatment of trophoblastic diseaseGynecologic Oncology, 1980
- Actinomycin D as the primary agent for gestational trophoblastic diseaseCancer, 1975